Exact Sciences stock enters new chapter after Abbott acquisition
Published on 08/21/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (US30063P1057) has transitioned into a new strategic phase within Abbott following the completion of an oncology diagnostics acquisition that is now reflected in Abbott’s most recent earnings and guidance as of August 21, 2026.
The latest quarterly report released for the three months ended in 2026 shows that Abbott reported second quarter 2026 sales growth of 13.0 percent on a reported basis and 4.8 percent on a comparable basis, paired with adjusted diluted earnings per share of $1.31, illustrating the broader earnings power of the group that now includes Exact Sciences.
In the same communication covering recent quarters, Abbott reaffirmed full year 2026 comparable sales growth guidance of 6.5 percent to a higher level while updating adjusted diluted earnings per share expectations, a frame that gives investors a fresh look at how Exact Sciences’ oncology diagnostics contributions may be integrated into the larger company’s results.
Acquisition brings Exact Sciences into Abbott’s growth engine
A detailed research compilation dated August 21, 2026 highlights Abbott’s first quarter 2026 figures, which include reported diluted earnings per share of $0.61 and adjusted diluted earnings per share of $1.15, reflecting 6 percent growth compared with the prior year period.
In that first quarter 2026 context, the documentation explicitly notes that Abbott completed the acquisition of Exact Sciences, aiming to establish a leading position in the fast growing oncology diagnostics market and signaling that Exact Sciences’ products and technologies are now part of Abbott’s expanding diagnostics portfolio.
For investors, one notable comparison is the shift between first and second quarter 2026 adjusted diluted earnings per share from $1.15 to $1.31, an increase of $0.16 that underscores momentum in Abbott’s earnings base as integration of new businesses, including Exact Sciences, proceeds.
Earnings guidance and revenue trajectory frame expectations
The same materials detailing Abbott’s second quarter 2026 results make clear that management is targeting full year 2026 comparable sales growth of 6.5 percent to a higher range, reinforcing expectations that the combined portfolio, with Exact Sciences included, should deliver mid single digit organic revenue expansion.
With second quarter 2026 reported sales growth at 13.0 percent against the prior year and comparable sales growth at 4.8 percent, investors gain a quantified view of how the overall revenue base is expanding, a useful benchmark when assessing how Exact Sciences’ oncology diagnostics revenue may contribute over time.
The progression of adjusted diluted earnings per share from $1.15 in first quarter 2026 to $1.31 in second quarter 2026 also implies that ongoing integration and operating leverage are supporting profit growth, even as Abbott invests in the Exact Sciences franchise to strengthen its diagnostics offering.
Operational integration of oncology diagnostics
Within Abbott’s broader diagnostics segment, the addition of Exact Sciences’ oncology focused tests is designed to deepen the company’s presence in early cancer detection and monitoring, providing laboratories and healthcare systems with more comprehensive diagnostic options.
Operationally, this integration likely involves aligning Exact Sciences’ research and development pipeline with Abbott’s established diagnostics platforms, harmonizing laboratory workflows, and expanding global distribution so that key tests can reach new geographies and clinical settings.
As laboratories adopt integrated oncology diagnostics solutions under Abbott’s umbrella, volumes in cancer screening and related testing can feed into the revenue and margin profile that is already visible in the second quarter 2026 results, where double digit reported sales growth offers a baseline reference.
Representative product: Cologuard colorectal cancer test
One representative product from the Exact Sciences portfolio that now sits within Abbott’s diagnostics ecosystem is the Cologuard colorectal cancer screening test, which is designed to detect altered DNA and blood in stool samples as an aid in early detection of colorectal cancer for average risk patients.
Cologuard provides a non invasive, at home screening option that can complement colonoscopy programs, and its inclusion inside a larger diagnostics group can help broaden access by leveraging established relationships with healthcare systems, payers, and laboratory networks.
As Abbott continues to report quarterly results and refine guidance, the performance of products such as Cologuard will be an important contributor to the growth trajectory in oncology diagnostics, potentially reinforcing the company’s ability to sustain mid single digit comparable sales growth as indicated for full year 2026.
Exact Sciences stock within the Abbott structure
While Exact Sciences as a standalone listed company is now part of Abbott’s corporate structure following the acquisition described in first quarter 2026 documentation, investors tracking Exact Sciences stock will focus on Abbott’s consolidated share price and market performance as the primary market reference.
The integration of Exact Sciences into Abbott means that key fundamentals for assessing the investment case, such as second quarter 2026 sales growth of 13.0 percent, comparable sales growth of 4.8 percent, and adjusted diluted earnings per share of $1.31, now serve as core metrics when evaluating how oncology diagnostics assets are contributing inside the combined issuer.
As of August 21, 2026, the story for Exact Sciences stock is therefore closely tied to Abbott’s reported quarterly earnings progression and full year 2026 guidance, with the quantified increase in adjusted diluted earnings per share between first and second quarter 2026 offering a concrete measure of profit momentum in the period immediately following the acquisition.
Fact box
Company: Exact Sciences
ISIN: US30063P1057
Ticker: integrated within Abbott’s listing
Exchange: integrated within Abbott’s primary exchange listing
Sector / Industry: Health care - Oncology diagnostics within broader medical devices and diagnostics
Index membership: reflected through Abbott’s index inclusion
